Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer

[1]  G. Stallone,et al.  The impact of age on intravesical instillation of Bacille Calmette–Guerin treatment in patients with high-grade T1 bladder cancer , 2019, Medicine.

[2]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[3]  T. D. de Reijke,et al.  The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. , 2014, European urology.

[4]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[5]  A. Finelli,et al.  Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer. , 2011, Urology.

[6]  E. Kikuchi,et al.  Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy? , 2011, Japanese journal of clinical oncology.

[7]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[8]  A. Sjölander.  Propensity scores and M‐structures , 2009, Statistics in medicine.

[9]  W. Savino,et al.  Can the Immune System Still Be Efficient in the Elderly? An Immunological and Immunoendocrine Therapeutic Perspective , 2008, Neuroimmunomodulation.

[10]  M. Terris,et al.  Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy. , 2008, Urologic oncology.

[11]  H. Herr.  Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. , 2007, Urology.

[12]  Y. Uekado,et al.  Intravesical instillation therapy with bacillus Calmette‐Guérin for superficial bladder cancer: Study of the mechanism of bacillus Calmette‐Guérin immunotherapy , 2007, International journal of urology : official journal of the Japanese Urological Association.

[13]  Brian J. Smith,et al.  The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. , 2006, The Journal of urology.

[14]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[15]  L. Seroude,et al.  Immunity and aging: the enemy within? , 2004, Aging cell.